PERRIGO Co plc
For the period ended Sep 26, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 26, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Revenue Recognition
NOTE 2 -REVENUE RECOGNITION
The following is a summary of our net sales by category (in millions):
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |
| Self Care | ||||
| Upper Respiratory | $195.4 | $211.1 | $571.1 | $607.1 |
| Digestive Health | 117.2 | 116.1 | 329.5 | 348.7 |
| Healthy Lifestyle | 164.2 | 161.4 | 464.7 | 473.1 |
| Pain & Sleep | 136.0 | 144.5 | 367.2 | 417.0 |
| Total Self Care | $612.7 | $633.1 | $1,732.6 | $1,845.9 |
| Specialty Care | ||||
| Skin Health | $126.7 | $140.3 | $440.4 | $460.2 |
| Women's Health | 55.7 | 50.9 | 175.7 | 163.2 |
| Total Specialty Care | $182.4 | $191.2 | $616.0 | $623.4 |
| Infant Formula | $80.7 | $89.3 | $271.4 | $259.1 |
| All Other(1) | $112.7 | $129.7 | $360.6 | $415.1 |
| Total net sales | $988.6 | $1,043.3 | $2,980.6 | $3,143.5 |
(1) Consists primarily of Oral Care, Dermacosmetics Business prior to sale (refer to Note 3 for details) and other miscellaneous or otherwise uncategorized product lines, none of which is greater than 10% of the segment net sales.
Note 2
The following table provides information about contract assets from contracts with customers (in millions):
| Balance Sheet Location | September 26, 2026 | December 31, 2025 | |
|---|---|---|---|
| Short-term contract assets | Prepaid expenses and other current assets | $32.7 | $37.3 |
We generated net sales in the following geographic locations(1) (in millions):
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |
| U.S. | $621.0 | $635.3 | $1,801.7 | $1,855.5 |
| Europe(2) | 344.8 | 384.0 | 1,108.0 | 1,217.9 |
| All other countries(3) | 22.8 | 24.0 | 70.9 | 70.1 |
| Total net sales | $988.6 | $1,043.3 | $2,980.6 | $3,143.5 |
(1) The net sales by geography are derived from the location of the entity that sells to a third party.
(2) Includes Ireland net sales of $12.7 million and $24.6 million for the three and nine months ended September 26, 2026, respectively, and $8.6 million and $29.4 million for the three and nine months ended September 27, 2025, respectively. Refer to Note 3 for details regarding the divestment of the Dermacosmetics Business impacting net sales in Europe.
(3) Includes net sales generated primarily in Australia and Canada.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.